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Background: The identification of groups at high risk is
fundamental to determine preventive strategies for skin cancer. Destructive reactive oxygen species
produced by UVA or chemical carcinogens are metabolized by a series of enzymes. Polymorphisms
of genes encoding for these enzymes may produce defective proteins with a diminished ability to
detoxify a wide range of carcinogens. Aims: To ascertain the influence and potential interactions of
several polymorphisms of genes encoding four important antioxidant GST enzymes in the
susceptibility to cancer among Brazilians. Material and methods: We compared the genotypes of
Glutathione S-Transferase mu, theta, pi and omega (GSTM1, GSTT1, GSTP1 and GSTO2) in a group
of 102 patients with skin lesions and 124 controls. Results: Patients with Basal Cell Skin Carcinoma
(BCC) presented the combined GSTM1-GSTT1+ genotype more frequently (49.1%) than controls
(29.8%) (Fisher test; p =0.04), conferring a 2.273 (Odds Ratio; 95% CI =1.199-4.308) higher risk for
BCC. We were not able to find any other association between genotypes or between any genotype
and the patients’ clinical features. Conclusions: The GST profile may help identify Brazilian
individuals at higher risk for BCC (Rev Méd Chile 2007; 135: 301-6).
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Influencia de polimorfismos de genes
de glutation s-transferasa
en la susceptibilidad a carcinoma
cutáneo de células basales
Antecedentes: La identificación de grupos en riesgo elevado es
fundamental en la determinación de las estrategias preventivas para el cáncer de la piel, el maligno
humano más común. Las especies reactivas destructivas del oxígeno producidas por UVA o los
agentes carcinógenos químicos son metabolizadas por una serie de enzimas. Los polimorfismos de
los genes que codifican para estas enzimas pueden producir las enzimas defectuosas con una
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Cancer of the skin is the most common malig-nancy in human beings. More than one
million cases occur every year and the worldwide
raise in this incidence to near epidemic proportio-
ns has led to increased morbidity and appreciating
costs in many countries1. Variations of skin cancer
incidence in different geographic and ethnic
groups suggest that environmental factors have a
strong influence in the skin tumorigenic process.
In fact, there are compelling clinical, epidemiolo-
gical and experimental evidences of environmen-
tal risk factors including ultraviolet (UVR) and
ionizing radiations, cell-transforming viruses,
immunosuppression and an increasing list of
chemical carcinogens1. However, humans vary
greatly in their likelihood of developing cancer in
response to the natural hazards that they are
constantly exposed to. Individual differences in
susceptibility to carcinogens play an essential role
in the development of sporadic tumors. The
biochemical basis for this susceptibility is related
to genetic polymorphisms that normally occur in
the general population regarding genes involved
in predisposition to a specific cancer, in the
metabolic activation or detoxification of environ-
mental genotoxins, and in controlling DNA repair
or cellular damage2-4. Among the several poly-
morphic genes encoding for enzymes involved in
free radical metabolism and biotransformation of
carcinogens that have been investigated as possi-
ble cancer risk modifiers, the glutathione S-
transferase gene system (GST) is one of the most
well-known4,5. It consists of a large multigenic
group of detoxifying enzymes whose activity,
catalyzing the conjugation of toxic and mutagenic
compounds with glutathione, is essential for cell
protection5,6. Four classes of isoenzymes have
been related to human malignancy: mu (GSTM),
pi (GSTP), omega (GSTO) and theta (GSTT).
Several studies, including our own, have shown
that individuals who are deletion homozygote for
GSTM1 or GSTT1, as well as individuals that
present GSTP1 variants (GSTv) resulting from an
aminoacid substitution (1105Valine) at exon 5 of
GSTP1, are at increased risk for a series of tumors2-
4,7,8. GST enzymes are implicated in the detoxifica-
tion of lipid and DNA products of UVR-derived
oxidative stress and allelic variants at GSTs are
associated with outcome of various oxidative-stress
related diseases, including skin cancer9-13.
More recently, genetic polymorphisms of
GSTO gene were described including GSTO2
N142D, a variant at base 42414. These polymor-
phisms have been related to a lower capacity of
the corresponding enzymes to metabolize arsenic,
a well-known skin carcinogenic chemical14,15.
The genetic profiles of each population, its
occupational pattern, alimentary and social characte-
ristics are fundamental in determining the susceptibi-
lity to some tumors. In addition, a balance between
several antioxidant enzymes may be more important
than the activity of a single enzyme alone for the
overall protective capacity against free radical-me-
diated damage, and deficiencies of one gene may be
partially compensated for by other related genes,
stressing the importance of determining the genetic
profile of specific populations. Brazilian population
is particularly interesting due to its highly heteroge-
neous background and racial admixture, and data on
the influence of its genetics on skin cancer suscepti-
bility are still scarce.
Hence, the present case-control prospective
study was designed to ascertain the influence and
potential interactions of genes encoding 4 impor-
tant antioxidant GST enzymes in the susceptibility
to cancer among Brazilians.
capacidad disminuida de desintoxicar una amplia gama de agentes carcinógenos. Objetivo: Este
estudio fue diseñado para comprobar las interacciones de la influencia y del potencial de varios
polimorfismos de los genes que codificaban 4 enzimas importantes del antioxidante GST en la
susceptibilidad al cáncer entre brasileños. Métodos: Comparamos los genotipos del mu del S-
Transferase del Glutathione, de la theta, de pi y de Omega (GSTM1, GSTT1, GSTP1 y GSTO2) en un
grupo de 102 lesiones de piel y de 124 controles. Resultados: Los pacientes con el carcinoma
basocelular (BCC) presentaron el genotipo combinado de GSTM1-GSTT1+ más frecuente (49,1%)
que los controles (29,8%) (Fisher test; p =0,04), confiriendo 2.273 (Odds Ratio 95% CI =1.199-
4.308) un riesgo más alto para BCC. No encontramos ninguna otra asociación entre los genotipos o
entre ningún genotipo y características clínicas de los pacientes. Conclusiones: Sugerimos que el
perfil de GST pueda ayudar a identificar a individuos brasileños en un riesgo más alto para BCC.
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PATIENTS AND METHODS
The study was approved by the Ethics Committees
of the University Hospital-School of Medicine of
the State University of Campinas (HC-FCM/UNI-
CAMP), and informed written consent was obtai-
ned from all individuals.
One hundred and two unrelated adult patients
consecutively referred for skin lesion evaluation,
that agreed to participate, were enrolled in the
study. The study population was composed of 29
squamous cell carcinomas (SCC), 59 basal cell
carcinoma (BCC), 5 malignant melanomas (MM)
and 9 non-malignant lesions (benign). All patients
were carefully examined and previous medical
conditions were particularly considered, especially
organ transplantation, immunosuppressive thera-
py, other malignancies and HIV infection.
A control group of 124 healthy blood donors
individuals (61 males and 63 females, 36 to 96 years
old, 64.12±19.34 years old) was selected from the
general population of our region through HC/FCM/
UNICAMP. Because of the high ethnic mixture and
heterogeneity of the Brazilian population, all indivi-
duals were classified into whites (or Euro-Brazilians)
and non-whites in accordance with the Brazilian
Institute of Geography and Statistics (IBGE, 2003).
Data on UV and possible chemicals exposure, ethnic
background as well as age and sex were considered
in order to obtain a control group similar to the
patients group. All individuals lived in urban areas.
Individuals suspected of any immunosuppressive
condition or to have been recurrently exposed to
any chemicals were excluded.
Blood specimens were obtained from all pa-
tients and control individuals simultaneously with
tissues samples from patients with lesions. Geno-
mic DNA was extracted from frozen specimens
and leukocytes separated from whole blood using
a standard proteinase-K-phenol-chloroform proto-
col. A multiplex-Polimerase Chain Reaction (PCR)
assay was used to simultaneously amplify the
GSTT1 and GSTM1 genes as previously descri-
bed8. GSTP1 and GSTO2 variants were studied
using PCR-RFLP (restriction fragment length poly-
morphism) assays. For GSTP1, the PCR was
performed in 25 µl volumes of a mixture contai-
ning 100 ng DNA, 10 µM of each primer, 10 mM
Tris-HCl (pH 8.0), 0.1 mM of each dinucleotide
triphosphate, 2.0 mM MgCl2 and 0.5 U Taq DNA
polymerase. Amplifications were carried out for 35
cycles of 94°C for 45 seconds, annealing tempera-
tures 62.4°C for 45 seconds and 72°C for 1 min,
with an initial denaturation step of 94°C for 5 min
and a final extension step of 72°C for 7 min using
a Termocycler MJPTC-200 PCR System. The pair of
primers for GSTP1 (5’ CCAGGCTGGGGCTCACA-
GACAGC3’/5’GGTCAGCCCAAGCCACCTGAGG3’)
amplified a fragment of 306bp. For GSTO2,
we used the same conditions as above with
annealing temperature of 62°C. The pair of pri-
mers for GSTO2 (5’ACTGAGAACCGGAACCA-
CAG3’/5’GTACCTCTTCCAGGTTG3’) amplified a
fragment of 280bp. RFLP was carried out using
Alw26I (BsmAI) and MboI enzymes for GSTP1
and GSTO2 assays respectively, according to the
manufacturer’s protocol (Fermentas Life Sciences).
The fragments were analyzed after electrophoresis
on a 3.0% agarose gel. Six samples from each
assay were directly sequenced and confirmed to
be the PCR predicted variants. Positive and negati-
ve control samples were included in all PCR and
RFLP runs to detect possible contamination pro-
blems, gel loading and typing inconsistencies.
Statistical analysis was conducted using SAS
(Statistical Analysis System, version 8.1, SAS Institute
Inc, Cary, NC, USA, 1999-2000). Associations were
assessed using 2X2 or 2Xn contingency table analy-
sis and Chi-square (χ2) or Fisher’s (F) exact tests
were used where appropriate. Kruskal-Wallis (KW)
test was used to compare age among groups. Mann-
Whitney or Wilcoxon tests were used to compare
age among different genotype groups. Odds ratio
(OR) and 95% confidence interval (CI) were used to
analyze the frequency of phenotypes since they
provide a measure of the strength of association,
compared to the control population. All tests were
conducted at the p =0.05 level of significance.
RESULTS
The clinical features of the control individuals and
the skin lesion patients are summarized in Table 1
where we also present the overall genotyping
profile of the studied groups. There were no
differences between the control and the skin
disease patients regarding gender (61 males and
63 females versus 53 males and 49 females), age
(64.12±19.34 years versus 64.11±15.64) and eth-
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Table 1. Distribution of the control individuals and patients. This distribution is according to their skin lesions’
histology, clinical features including age (X±SD in years), gender (F: female; M: male), ethnicity (W: white, NW:
non-white), and the corresponding genotype for GSTM1, GSTT1, GSTP1 and GSTO2. Genotypes are
represented as + (present) or - (absent) according to the presence of the allele or WT, HET and HO according to
the presence of a wild type, a heterozygous or a homozygous variant form of the gene, respectively
Histology Clinical characteristics Genotype
Age Sex Ethnicity GSTM1 GSTT1 GSTP1 GSTO2
(x±SD) M F W NW + - + - WT HET HO WT HET HO
Controls
(N =124) 64.12±19.34 61 63 98 26 72 52 96 28 60 46 18 40 62 22
Non-malignant
(N =9) 61.66±20.44 3 6 9 0 5 4 7 2 7 1 1 3 5 1
BCC
(N =59) 67.42±11.18 33 26 58 1 25 34 49 10 35 20 4 25 26 8
SCC
(N =29) 56.16±19.23 16 13 29 0 28 13 22 7 14 13 2 12 12 5
MM
(N =5) 75.8±6.94 1 4 4 1 4 1 2 3 1 1 3 2 2 1
Table 2. Comparison among the distribution of the different combinations of GSTT1 and GSTM1
genotypes in the control population and the skin benign and malignant cases, including basal cell
carcinoma (BCC), squamous cell carcinomas (SCC) and malignant melanomas (MM)
Genotype Population Benign BCC SCC MM
N (%) N % N % N % N %
GSTT1-GSTM1- 15 (12.09) 1 (11.11) 5 (8.47) 2 (6.89) 1 (20.00)
GSTT1-GSTM1+ 13 (10.48) 1 (11.11) 5 (8.47) 5 (17.24) 2 (40.00)
GSTT1+GSTM- 37 (29.83) 3 (33.33) 29 (49.15) 11 (37.93) 0
GSTT1+GSTM1+ 59 (47.58) 4 (44.44) 20 (33.89) 11 (37.93) 2 (40.00)
Total 124 9 59 29 5
nicity (118 white and 6 non-white versus 100
white and 2 non-white individuals) (F: p <0.0001).
Genotyping of the different types of cancer is
presented in Tables 1 and 2. The combined
GSTT1+GSTM1- genotype was more frequent
among BCC patients (49.1%) than in the control
group (29.8%) (F: p =0.04). Hence, this genotype
conferred a 2.273 (OR: 95% CI =1.199-4.308) higher
risk for BCC compared to other GSTM1 and GSTT1
combinations of genotypes. GSTP1 did not differ in
control and skin benign lesions’ patients or non-
melanoma cancers. However, 3 out of the 5 MM
patients presented a homozygous GSTP1 variant, in
contrast to the low prevalence of this variant in the
control population (14.5%) (F: p =0.0303). The
presence of a homozygotic variant of GSTP1 gene
conferred an 8.8 times higher susceptibility to MM
(OR =8.883; 95% CI =1.378-56.636).
We were not able to find any significant difference
in the rate of any other GST normal or variant alleles in
the different types of malignant tumors. There was no
association between any other genotypes or between
any genotype and the patients’ clinical features.
DISCUSSION
Cancer of the skin is one of the most powerful
examples of how human tumors are a result of the
interaction between environmental factors and
Rev Méd Chile 2007; 135: 301-306
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personal genetic susceptibility. The most common
factor involved in the pathogenesis of non-mela-
noma skin cancers is the exposure to UVR.
However, exposure to large amounts of arsenic,
industrial tar, coal, paraffin, certain types of oil,
and other chemicals may increase the risk to non-
melanoma skin tumors too1. One of the mechanis-
ms by which UV light mediates its carcinogenic
effect is by stimulating the production of reactive
oxygen species, which trigger both DNA damage
and abnormal cytoplasmic signal transduction16.
Glutathione S-transferases are an important
group of antioxidant enzymes that may have
evolved to protect cells against reactive oxygen
metabolites. The present study demonstrates that
the combined GSTT1+GSTM1- genotype predis-
poses to the development of BCC. Also, the
presence of a GSTP1 variant in homozygosis
increased the risk for MM, although the small
number of cases examined prevents any further
conclusion. On the other hand, the present geno-
typing profile of skin lesions’ patients and controls
resulted similar to the genetic profile described
earlier by our own group and also to other reports
on different types of tumors in Brazil7,8,17-20.
The precise mechanism of action of GST
enzymes is as yet largely unknown but it is
accepted that they act via modification of DNA
and lipid damage to key tumor suppressor genes
or by protection against relevant carcino-
gens4,5,16,21. GSTM1 null genotype has been asso-
ciated to non-melanoma carcinoma risk, especially
in males with multiple BCC and immunosuppres-
sed patients9,10,12. In addition, in patients with
systemic lupus erithematosus, GSTM1 null was
associated with increased production of anti-Ro
antibodies, a phenotype associated with marked
photosensitivity22. Our data suggest a protective
effect of the GSTT1 null genotype when combi-
ned to GSTM1 null genotype. Other studies have
suggested that some detoxifying enzymes may
exert a protective effect on some types of tumors,
depending on the source of exposure23. For
instance, in vitro studies, mostly conducted on
metabolites of butadiene, confirm a protective
action of GSTT123. Indeed, some epoxides are
scavenged in-vitro systems by GSTT1 and are less
dangerous for GSTT1 positive subjects23.
There are evidences for a role of GSTP1 in the
pathogenesis of skin malignancies. GSTP1 is a
major antioxidant in both the epidermis and the
dermis, and is overexpressed in a variety of
preneoplastic and neoplastic tissues24. However,
our data do not support an important role of
GSTP1 in non-melanoma skin cancer and the
small number of MM we studied prevents any
conclusion regarding this type of tumor.
We included GSTO2 polymorphism in this study
because of GSTO variants lower capacity to biotrans-
form inorganic arsenic14,15. Arsenic is a notorious
environmental skin carcinogen and contamination of
drinking water with inorganic arsenic is a worldwide
health problem24. A recent expression pattern analy-
sis revealed that GSTO2 was ubiquitously expressed
at a low level in all tissues and suggested that it may
play an important role in cellular signaling25. Howe-
ver, our data do not indicate an important role of
GSTO2 in skin cancer carcinogenesis.
It is important to note that the influence of any
single genetic polymorphism may have a small
contribution on the susceptibility to cutaneous malig-
nancy that is influenced by a multitude of genes that
may either protect against or increase the susceptibili-
ty to an increasing list of chemical, physical and
biological carcinogens. Also, the different GST enzy-
mes have specific endogenous and environmental
substrates, a fact that helps explain the difference rate
for many cancers described in different populations.
In conclusion, we observed an association
between GSTM1 and GSTT1 genotype and the
risk for BCC. Although the risk presented by this
association had a relatively small OR, it may help
to understand the basis of genetic and environ-
mental factors known to predispose to skin
cancer, and, therefore, sort out individuals that
deserve a special medical attention. Further stu-
dies including a larger number of patients are
necessary to clarify the role of these genotypes in
skin cancer susceptibility and their interaction
with genotoxic or cytotoxic agents.
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